Chinese patent expiration dates draw closer for Novo Nordisk

In coming years, Novo Nordisk will take blows in the shape of several patents terminating on the second-biggest market for the firm, a Danish media reports.
Photo: Thomas Borberg
Photo: Thomas Borberg
by mikkel aabenhus hemmingsen, translated by daniel pedersen

After a string of years characterized by growth for Novo Nordisk, in 2022, the Danish pharmaceutical firm has been hit by a large pricing reform in China. More challenges loom on the horizon in the country, which is the firm’s second-biggest market, as reported by Danish media Finans.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading